Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • inderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Följda bolag
    • Teamet
Regulatoriskt pressmeddelande

Bulletin from Simris Group AB’s Extraordinary General Meeting

Simris Group
Ladda ner börsmeddelandet

Simris Group AB (publ), reg. no. 556841–9187 (the "Company") held an extraordinary general meeting on 20 January 2025. Below follows a summary of the resolutions that were passed at the meeting.

Resolution on entering into loan agreements
The general meeting resolved to enter into loan agreements with Frank Puccio amounting to EUR 50,000, Royce CoLabs AB, a company controlled by Jonathan Royce, amounting to EUR 10,000, Magnus Högström amounting to EUR 30,000, Arminnovate Ltd, a company controlled by Dr Alexis Roberts-McIntosh, Amounting to EUR 20,000 and Christoffer Tell AB, a company controlled by Christoffer Tell amounting to EUR 30,000 for a total loan amount of EUR 140,000 and to instruct the board of directors to execute the loan agreements (“Loan Agreements”).
 
The Loan Agreements shall have a monthly interest rate of one (1) per cent and a maturity date of 31 December 2025. The lenders shall have a right to convert all outstanding loan and interest to B-shares at a subscription price of SEK 0.05 per B-share. If the Company conducts a capital raise before 31 December 2025 the subscription price shall be lowered to correspond with the subscription price in such capital raise.
 
The board of directors submitted the Loan Agreements to the general meeting for approval due to conflict of interests of its members according to the Swedish Companies Act.

Contact Details:
Dr Alexis Roberts-McIntosh
CEO Simris Group AB
Email: ir@simris.com
Mobile: +44 (0) 7940 585298
www.simrisgroup.com

About Simris Group AB (PUBL):
Simris Group is a biologics company identifying and commercialising high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals, dietary supplements and cosmetics. 

Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.

Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.

Attachments
Bulletin from Simris Group AB’s Extraordinary General Meeting

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Our team
  • Inderes som en investering
  • Tjänster för börsbolag
Our platform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • inderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Följda bolag
    • Teamet